Written By: Joshua Nubla, PharmD, NCODA Download Here  Description: This PQI is developed to provide guidance to genomic testing with respect to selpercatinib. Background: RET-altered cancers include both RET fusions and RET mutations. Both alterations involve activating RET signaling pathways that promote unwanted cell proliferation in cancers. NCCN guidelines for NSCLC include a Category 2A […]

Written By: Elizabeth Ledbetter, PharmD DOWNLOAD HERE Description: The purpose of this PQI is to help provide awareness of larotrectinib and educate on management techniques.  Background: Larotrectinib is indicated for the treatment of adult and pediatric patients with solid tumors that: Have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance […]

Written By: Joshua Nubla, PharmD, NCODA Download Here Description: This PQI will discuss the initiation and management of patients receiving avapritinib.   Background: Avapritinib is a tyrosine kinase inhibitor indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. […]

Written by Neal Dave, PharmD, Texas Oncology Download Here Description: This PQI will review appropriate patient identification and management of Polycythemia Vera (PV) with the use of ruxolitinib therapy. Background: Common treatments for PV are aspirin, phlebotomy, hydroxyurea, interferon (not commonly used), or a JAK2 inhibitor, ruxolitinib. Hydroxyurea (HU) is considered the gold standard treatment […]

Written by: Bryan J. Brinda, PharmD Download Here Description: This PQI will discuss proper patient selection and management of adverse events related to the administration of oral gilteritinib pharmacotherapy in patients with relapsed/refractory AML that have an FMS-like tyrosine kinase 3 (FLT3) mutation as detected by an  FDA-approved test. Optimal patient identification, dosing, and follow-up […]

Written by: Tammy McClellan, PharmD Download Here Description: The purpose of this PQI is to expand on therapy management of ibrutinib when used in combination with obinutuzumab. Background: This FDA has extended the indications for ibrutinib; already approved as a single agent OR in combination with bendamustine and rituximab. Ibrutinib is indicated for Mantle Cell […]

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer – FDA approval based on phase 3 COSMIC-311 pivotal trial, which demonstrated significant improvement in progression-free survival with CABOMETYX versus placebo – – Exelixis is prepared to fully support expanded indication immediately – – Application approved well ahead of […]

Written by: Joseph Bubalo PharmD, Oregon Health & Science University DOWNLOAD HERE Description: The purpose of this PQI is to summarize the process for initiating and monitoring ripretinib therapy in patients with advanced gastrointestinal stromal tumor (GIST) who have received 3 or more prior kinase inhibitors including imatinib. Background: Ripretinib is a tyrosine kinase inhibitor […]

Written by: Martina Fraga, PharmD Download Here Description: The purpose of this PQI is to highlight effective practices to ensure ovarian cancer patients are identified, tested, tracked, and offered a PARP inhibitor when appropriate. Background: In gynecologic cancer patients, PARP inhibitors (PARP-I), have shown increased progression free survival (PFS) and, in some cases, overall survival. Misconceptions may […]

Written By: Kayla Randle, PharmD, BCOP Download Here  Description: Pralsetinib is an oral Rearranged during Transfection (RET) tyrosine kinase inhibitor (TKI) that inhibits oncogenic RET fusions and mutations.1 The purpose of this PQI is to review pralsetinib’s role in therapy, management of adverse effects and potential drug interactions, and to recommend patient follow up associated […]

Written by: Natasha Heimbigner, PharmD, Summit Cancer Centers Download Here Description of PQI: The use of immunotherapy in cancer treatment has expanded tremendously over the last several years. The most common adverse effects include dermatologic, gastrointestinal, hepatic, and endocrine toxicities. Management of immunotherapy-related rash is an important intervention for the patient’s quality of life and […]

Written by Jennifer M. Hasiak O’Doherty, PharmD, Hematology Oncology Consultants, PC Download Here Description: This PQI will highlight strategies for appropriate dosing and management of adverse effects related to trifluridine and tipiracil treatment in metastatic colorectal cancer. Background: Trifluridine and Tipiracil is indicated for the treatment of patients with metastatic colorectal cancer who have been […]